TY - JOUR
T1 - Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from high-risk patients
AU - Isaacs, Claudine
AU - Cavalli, Luciane R.
AU - Cohen, Yoram
AU - Pennanen, Marie
AU - Shankar, Lalita K.
AU - Freedman, Matthew
AU - Singh, Baljit
AU - Liu, Minetta
AU - Gallagher, Ann
AU - Rone, Janice D.
AU - Dickson, Robert B.
AU - Sidransky, David
AU - Haddad, Bassem R.
N1 - Funding Information:
This work was supported by the following grants: US Department of Defense (DOD) Breast Cancer Research Grant (DAMD17-01-1-0525), NCI (R21 CA87344-01) and Friends you can count on Foundation to BRH; National Institutes of Health SPORE Grant (2-P50-CA58185) to RBD; and Swing for the Cure Grant to CI. We thank the Familial Cancer Registry and the Histopathology and Tissue Shared Resources of Lombardi Comprehensive Cancer Center, which are partially supported by National Institutes of Health Grant 1P30-CA-51008 (Cancer Center Support Grant, to Lombardi Comprehensive Cancer Center).
PY - 2004/3/1
Y1 - 2004/3/1
N2 - We describe a method for the isolation of free DNA from ductal lavage (DL) and nipple aspirate fluid (NAF), and its evaluation for the presence of LOH at the BRCA1 and FHIT genes and for mitochondrial DNA (mtDNA) mutations at the D310 marker, to improve early detection of breast cancer. We evaluated 26 DL and six NAF samples from 14 women of known BRCA1 status, who have no clinical evidence of breast tumors: nine mutation carriers and five non-carriers. LOH studies at the BRCA1 locus were possible in 19/26 DL samples, and at the FHIT locus in 16/26 samples. In 4/9 mutation carriers we found LOH at the BRCA1 allele, and in two of these we also found LOH at the FHIT allele. In one of the mutation carriers with BRCA1 LOH, invasive breast cancer was subsequently detected, and the tumor showed the same LOH as the DL. In one of the true negatives, BRCA1 and FHIT LOH were detected. The mitochondrial studies were possible in all 26 DL samples and a somatic mutation was found in 3/9 carriers, two of whom also had LOH at the BRCA1 locus, and in none of the non-carriers. mtDNA mutation evaluation was possible in 4/6 NAF samples. The NAF and DL results were concordant. One NAF sample from a BRCA1 patient showed a mtDNA mutation. Our data demonstrates the feasibility of performing molecular studies using the free DNA present in the ductal fluid, while the intact cells can be used for cytologic studies.
AB - We describe a method for the isolation of free DNA from ductal lavage (DL) and nipple aspirate fluid (NAF), and its evaluation for the presence of LOH at the BRCA1 and FHIT genes and for mitochondrial DNA (mtDNA) mutations at the D310 marker, to improve early detection of breast cancer. We evaluated 26 DL and six NAF samples from 14 women of known BRCA1 status, who have no clinical evidence of breast tumors: nine mutation carriers and five non-carriers. LOH studies at the BRCA1 locus were possible in 19/26 DL samples, and at the FHIT locus in 16/26 samples. In 4/9 mutation carriers we found LOH at the BRCA1 allele, and in two of these we also found LOH at the FHIT allele. In one of the mutation carriers with BRCA1 LOH, invasive breast cancer was subsequently detected, and the tumor showed the same LOH as the DL. In one of the true negatives, BRCA1 and FHIT LOH were detected. The mitochondrial studies were possible in all 26 DL samples and a somatic mutation was found in 3/9 carriers, two of whom also had LOH at the BRCA1 locus, and in none of the non-carriers. mtDNA mutation evaluation was possible in 4/6 NAF samples. The NAF and DL results were concordant. One NAF sample from a BRCA1 patient showed a mtDNA mutation. Our data demonstrates the feasibility of performing molecular studies using the free DNA present in the ductal fluid, while the intact cells can be used for cytologic studies.
KW - Breast cancer
KW - Ductal lavage
KW - Loss of heterozygosity
KW - Mitochondrial mutations
KW - Nipple aspirate fluid
UR - http://www.scopus.com/inward/record.url?scp=12144288294&partnerID=8YFLogxK
U2 - 10.1023/B:BREA.0000018406.03679.2e
DO - 10.1023/B:BREA.0000018406.03679.2e
M3 - Article
C2 - 14999140
AN - SCOPUS:12144288294
SN - 0167-6806
VL - 84
SP - 99
EP - 105
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 2
ER -